Retatrutide (LY-3437943) is the most potent weight loss research compound to emerge from clinical trials to date. A triple GLP-1/GIP/glucagon receptor agonist developed by Eli Lilly, it produced an average 24.2% body weight reduction in a landmark Phase 2 trial published in the New England Journal of Medicine. Here is everything the science shows — and where to buy Retatrutide in South Africa.
Retatrutide (INN: retatrutide; development code: LY-3437943) is a novel once-weekly injectable investigational compound developed by Eli Lilly and Company. Unlike existing GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro), which target one or two receptors respectively, Retatrutide simultaneously activates three hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor.
This triple mechanism gives Retatrutide a uniquely comprehensive metabolic action — suppressing appetite through GLP-1 and GIP pathways while simultaneously increasing energy expenditure via glucagon receptor activation. The result, as the 2023 Phase 2 trial demonstrated, is a magnitude of weight loss that significantly exceeds any previously studied or approved compound.
338 adults with obesity (BMI ≥30) randomised to once-weekly Retatrutide or placebo. At the highest dose (12mg), participants achieved a mean weight reduction of 24.2% from baseline at 48 weeks — the greatest weight loss ever recorded in a clinical trial for an anti-obesity medication.
Read on NEJM →Weight loss was clearly dose-dependent: 4mg group achieved 8.7% reduction, 8mg group achieved 17.3%, and 12mg group achieved 24.2% — all significantly greater than placebo (2.1%). Weight loss was still accelerating at 48 weeks, suggesting greater reductions may be possible with longer treatment.
Read on NEJM →Beyond weight loss, participants showed significant improvements in waist circumference, fasting insulin levels, HbA1c, blood pressure, and triglycerides — demonstrating broad cardiometabolic benefit beyond weight reduction alone.
Read on NEJM →Retatrutide is currently in Phase 3 clinical trials (TRIUMPH programme) evaluating long-term efficacy and safety in obesity, type 2 diabetes, and MASH (metabolic dysfunction-associated steatohepatitis) across multiple global sites.
View on ClinicalTrials.gov →In a randomised trial for metabolic dysfunction-associated steatotic liver disease, Retatrutide produced substantial reductions in liver fat content alongside significant weight loss, supporting its potential beyond obesity into metabolic liver disease.
Read on Nature Medicine →A pooled analysis of randomised controlled trials confirmed the efficacy and safety of Retatrutide as a GLP-1, GIP, and glucagon receptor agonist for obesity treatment across the studied dose range.
Read on PMC →The most common side effects reported in the NEJM Phase 2 trial were gastrointestinal in nature and consistent with the GLP-1 class:
Retatrutide 30mg currently on special at R1,500 (normal R1,700). 99% purity, COA available, bacwater included. Fast nationwide delivery across South Africa from Helix Collective SA.